Assembly Biosciences Presents New Preclinical Data Highlighting Investigational Helicase-Primase Inhibitors at International Herpesvirus Workshop
15 juil. 2024 08h00 HE
|
Assembly Biosciences, Inc.
– Data from both ABI-5366 and ABI-1179, novel long-acting helicase-primase inhibitor candidates for recurrent genital herpes, to be presented – – Poster presentation highlights key preclinical data...
Global Radiation Therapy Market with Focus on LINAC, 2024 Market Report: A $14.18 Billion Market in 2028, Registering a Projected CAGR of 6.75% During 2024-2028
12 juil. 2024 10h26 HE
|
Research and Markets
Dublin, July 12, 2024 (GLOBE NEWSWIRE) -- The "Global Radiation Therapy Market with Focus on LINAC: Insights & Forecast (2024-2028)" report has been added to ResearchAndMarkets.com's offering. ...
Cognizant and Yseop announce plan to partner to scale medical writing through Generative AI
11 juil. 2024 09h00 HE
|
Yseop
NEW YORK, July 11, 2024 (GLOBE NEWSWIRE) -- Cognizant and Yseop, a leading artificial intelligence (AI) software company, have announced a plan to partner to help accelerate and scale the delivery...
[Latest] Global Wood Pallets Market Size/Share Worth USD 21.2 Billion by 2033 at a 4.6% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
09 juil. 2024 12h30 HE
|
Custom Market Insights
Austin, TX, USA, July 09, 2024 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Wood Pallets Market Size, Trends and Insights By Product (Block Wooden Pallet,...
Io Therapeutics, Inc., announces presentation of data on induction of tumor growth inhibiting anti-cancer immune responses in multiple types of cancers by a IRX5010, a novel retinoic acid nuclear receptor agonist compound
08 juil. 2024 20h00 HE
|
Io Therapeutics, Inc.
Io Therapeutics, Inc presented studies in multiple cancers with its novel drug that inhibits tumor growth by promoting tumor infiltrating T-lymphocytes
Amarin Partner EddingPharm Receives Regulatory Approval for VASCEPA® (Icosapent Ethyl) in Mainland China for Cardiovascular Risk Reduction (CVRR)
08 juil. 2024 07h30 HE
|
Amarin Corporation plc
-- VASCEPA Approved by the National Medical Products Administration (NMPA) To Reduce the Risk of Cardiovascular Events as an Adjunct to Statin Therapy in Adult Patients with Elevated Triglyceride (TG)...
Global Pharmaceutical Logistics Market Size To Worth USD 191.18 Billion By 2033 | CAGR Of 7.64%
05 juil. 2024 16h00 HE
|
SPHERICAL INSIGHTS LLP
New York, United States , July 05, 2024 (GLOBE NEWSWIRE) -- The Global Pharmaceutical Logistics Market Size is Expected to Grow from USD 91.60 Billion in 2023 to USD 191.18 Billion by 2033, at a...
Global Low Intensity Sweeteners Market Size is Estimated to Grow $3.6 billion by 2026
04 juil. 2024 20h00 HE
|
MarketsandMarkets Research Pvt. Ltd.
Chicago, July 04, 2024 (GLOBE NEWSWIRE) -- According to MarketsandMarkets, the global low intensity sweeteners market size is estimated to be valued at USD 2.9 billion in 2021 and is projected to...
Drafting Commercial Contracts for the Pharmaceutical Industry: 2-Day Online Training Course (November 20-21, 2024) - An In-Depth Examination of IP, Competition, and Legal Issues in Pharma Agreements
03 juil. 2024 11h35 HE
|
Research and Markets
Dublin, July 03, 2024 (GLOBE NEWSWIRE) -- The "Drafting Commercial Contracts for the Pharmaceutical Industry Training Course" training has been added to ResearchAndMarkets.com's offering. In such...
Development of Combination Products: Critical Interactions - 4-Day Online Seminar (October 3-4, 2024) Covering EU/US Drug-Device Regulations, Quality Processes, Regulatory Strategy Overview
03 juil. 2024 10h59 HE
|
Research and Markets
Dublin, July 03, 2024 (GLOBE NEWSWIRE) -- The "Development of Combination Products: Critical Interactions Training Course" conference has been added to ResearchAndMarkets.com's offering. ...